Literature DB >> 10092113

Strain dependency of TGFbeta1 function during embryogenesis.

S Kallapur1, I Ormsby, T Doetschman.   

Abstract

There is incomplete penetrance to Tgfb1 knockout phenotypes. About 50% of Tgfb1 homozygous mutant (Tgfb1-/-) and 25% of Tgfb1 heterozygous (Tgfb1+/-) embryos die during embryogenesis. In a mixed NIH/Ola x C57BL/6J/Ola x 129 background partial embryonic lethality of the Tgfb1-/-embryos occurs due to defective yolk sac vasculopoiesis and/or hematopoiesis. We show here that on a predominantly CF-1 genetic background, lack of TGFbeta1 causes a pre-morula lethality in about 50% of the null embryos. This partial lethality is not reversed by transfer of Tgfb1-/- embryos to Tgfb1-/+ hosts. The extent of embryonic lethality in Tgfb1-/- embryos ranges in a background dependent manner from 20% to 100%. Based on these and other studies it is clear that TGFbeta1 acts at two distinct phases of embryogenesis: pre-implantation development and yolk sac vasculogenesis/hematopoiesis. The susceptibility for the pre-implantation lethality depends on a small number of genetic modifiers since a small number of backcrosses onto the high susceptibility strain C57BL/6 leads to complete penetrance of the lethality.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092113     DOI: 10.1002/(SICI)1098-2795(199904)52:4<341::AID-MRD2>3.0.CO;2-N

Source DB:  PubMed          Journal:  Mol Reprod Dev        ISSN: 1040-452X            Impact factor:   2.609


  18 in total

Review 1.  Supermodels and disease: insights from the HHT mice.

Authors:  C L Shovlin
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Comment on Levanon et al., "Runx3 knockouts and stomach cancer", in EMBO reports (June 2003).

Authors:  Suk Chul Bae; Yoshiaki Ito
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

Review 3.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

Review 4.  Probing human cardiovascular congenital disease using transgenic mouse models.

Authors:  Paige Snider; Simon J Conway
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

5.  TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.

Authors:  Jo El J Schultz; Sandra A Witt; Betty J Glascock; Michelle L Nieman; Peter J Reiser; Stacey L Nix; Thomas R Kimball; Thomas Doetschman
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

6.  Elimination of both CD4+ and CD8+ T cells but not B cells eliminates inflammation and prolongs the survival of TGFbeta1-deficient mice.

Authors:  Ramireddy Bommireddy; Sandra J Engle; Ilona Ormsby; Gregory P Boivin; George F Babcock; Thomas Doetschman
Journal:  Cell Immunol       Date:  2005-03-29       Impact factor: 4.868

7.  TGF beta 1 inhibits Ca2+-calcineurin-mediated activation in thymocytes.

Authors:  Ramireddy Bommireddy; Ilona Ormsby; Moying Yin; Gregory P Boivin; George F Babcock; Thomas Doetschman
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

8.  Heterozygous knockout of transforming growth factor-β1 protects Dahl S rats against high salt-induced renal injury.

Authors:  Chun Cheng Andy Chen; Aron M Geurts; Howard J Jacob; Fan Fan; Richard J Roman
Journal:  Physiol Genomics       Date:  2012-12-18       Impact factor: 3.107

9.  Myocardial deletion of Smad4 using a novel α skeletal muscle actin Cre recombinase transgenic mouse causes misalignment of the cardiac outflow tract.

Authors:  Mohamad Azhar; Pei-Yu Wang; Tony Frugier; Kyoko Koishi; Chuxia Deng; Peter G Noakes; Ian S McLennan
Journal:  Int J Biol Sci       Date:  2010-09-20       Impact factor: 6.580

Review 10.  Influence of genetic background on genetically engineered mouse phenotypes.

Authors:  Thomas Doetschman
Journal:  Methods Mol Biol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.